Thiazolidinediones and cardiovascular outcomes in type 2 diabetes Reply

被引：0
|
作者：
Singh, S. [1 ]
Furberg, C. D. [1 ]
机构：
[1] Wake Forest Univ, Winston Salem, NC 27109 USA
来源：
HEART | 2009年 / 95卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：332 / 332
页数：1
相关论文
共 50 条
  • [21] Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    Wiviott, S. D.
    Raz, I.
    Bonaca, M. P.
    Mosenzon, O.
    Kato, E. T.
    Cahn, A.
    Silverman, M. G.
    Zelniker, T. A.
    Kuder, J. F.
    Murphy, S. A.
    Bhatt, D. L.
    Leiter, L. A.
    McGuire, D. K.
    Wilding, J. P. H.
    Ruff, C. T.
    Gause-Nilsson, I. A. M.
    Fredriksson, M.
    Johansson, P. A.
    Langkilde, A-M.
    Sabatine, M. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (04): : 347 - 357
  • [22] Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
    Cannon, Christopher P.
    Pratley, Richard
    Dagogo-Jack, Samuel
    Mancuso, James
    Huyck, Susan
    Masiukiewicz, Urszula
    Charbonnel, Bernard
    Frederich, Robert
    Gallo, Silvina
    Cosentino, Francesco
    Shih, Weichung J.
    Gantz, Ira
    Terra, Steven G.
    Cherney, David Z. I.
    McGuire, Darren K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15): : 1425 - 1435
  • [23] Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Marso, Steven P.
    Daniels, Gilbert H.
    Brown-Frandsen, Kirstine
    Kristensen, Peter
    Mann, Johannes F. E.
    Nauck, Michael A.
    Nissen, Steven E.
    Pocock, Stuart
    Poulter, Neil R.
    Ravn, Lasse S.
    Steinberg, William M.
    Stockner, Mette
    Zinman, Bernard
    Bergenstal, Richard M.
    Buse, John B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 311 - 322
  • [24] Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes
    Kumar, Hari K. V. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25): : 2478 - 2478
  • [25] Microvascular outcomes in type 2 diabetes Reply
    Zoungas, Sophia
    Gerstein, Hertzel C.
    Holman, Rury R.
    Reaven, Peter
    Woodward, Mark
    Arima, Hisatomi
    Coleman, Ruth L.
    Chalmers, John
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08): : 580 - 580
  • [26] Effects of thiazolidinediones on the triad of type 2 diabetes mellitus, insulin resistance and cardiovascular disease
    John, Y. C.
    Ilag, Chan Liza
    Tan, Meng H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 78 : S3 - S13
  • [27] MODELLING CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES IN THE ERA OF CARDIOVASCULAR OUTCOMES TRIALS
    McEwan, P.
    Chubb, B.
    Bennett, H.
    VALUE IN HEALTH, 2017, 20 (09) : A747 - A747
  • [28] Thiazolidinediones in type 2 diabetes: A cardiology perspective
    Khanderia, Ujjaini
    Pop-Busui, Rodica
    Eagle, Kim A.
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (10) : 1466 - 1474
  • [29] Thiazolidinediones for initial treatment of type 2 diabetes?
    Nathan, David M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23): : 2477 - 2480
  • [30] Thiazolidinediones and blood lipids in type 2 diabetes
    van Wijk, JPH
    de Koning, EJP
    Martens, EP
    Rabelink, TJ
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (10) : 1744 - 1749
12345